6
SENDERRA Specialty Pharmacy

Enrollment Form

Atopic Dermatitis

Prescriber:	NPI:
Supervising Physician:	NPI:
Address:	Tax ID:

		A-H		Supervi	Silig i liysiciali.			141 1.		
SENDERRA Physician Offices Call:			Address:				Tax ID:			
855-460-7928 Specialty Pharmacy			Phone: Fax:							
3/12 E. Plano I Plano, TX 7507	Parkway, Ste. 200 74	Fax: 888	-777-5645	Contact:						
This prescription for	rm is to be sent & received via fa	x .		DATIE	NT INFORMATION					
Name:						DOB:		SS#:		
				Trans M Trans F Other/			/	_		
Street: City:			State:				ZIP:			
Phone: Alt. Phone:					☐ English ☐ Spa	nish Other: _		Wt.:	Ht.:	
Has the nation	nt received a loading dos	a/startor kit?	Uves Start Date		RESCRIPTION	HID TO: Datio	nt's Home Doct	tor's Office 🗆 C	Other:	
Drug					Direc	tions & Quantity	iit s flome — Doci	tor s office — c	/tilei	Refills
			□ INITIAL: Inject 600 mg SQ on day 1 (Quantity: 2)							
	☐ 300 mg Autoinjector		MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2)							
Adbry®			MAINTENANCE: Inject 300 mg SQ every 4 weeks (Quantity: 1) ***Intended for patients who weigh below 100 kg who achieve clear/almost clear skin after 16 weeks of treatment***							
Addity			□ INITIAL: Inject 600 mg SQ on day 1 (Quantity: 4)							
	☐ 150 mg Pre-filled Sy	ringe 🔲 I	☐ MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 4)							
			MAINTENANCE: Inject 300 mg SQ every 4 weeks (Quantity: 2) ***Intended for patients who weigh below 100 kg who achieve clear/almost clear skin after 16 weeks of treatment***							
Cibingo®	☐ 100 mg Tablet	I	☐ Take 100 mg PO once daily (Quantity: 30)							
Oibiliqo	☐ 200 mg Tablet		Take 200 mg PO once daily (Quantity: 30) ***Intended for patients who have not achieved adequate response with 100 mg daily dose***							
Dupixent®	300 mg Pre-filled Sy	9-	INITIAL: Inject 600 mg SQ on day 1 (Quantity: 2)							
	□ 300 mg Pen		MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2)							
		I	□ INITIAL: Inject 500 mg (two 250 mg injections) SQ at week 0 & week 2 (Quantity: 4)							
Ebglyss™	250 mg Pre-filled Sy		□ INDUCTION: Inject 250 mg SQ every 2 weeks starting at week 4 (weeks 4-14) (Quantity: 2 plus 2 refills)							
	□ 250 mg Pen		FINAL INDUCTION: Inject 250 mg SQ (week 16) (Quantity: 1)							
			☐ MAINTENANCE: Inject 250 mg SQ every 4 weeks (thereafter) (Quantity: 1) ☐ MAINTENANCE: Inject 250 mg SQ every 2 weeks (thereafter) (Quantity: 2)							
	☐ 2% Ointment 60 gm		MAINTENANCE:	Inject 250	mg SQ every 2 weeks	s (thereafter) (Qua	ntity: 2)			
Eucrisa®	2% Ointment 100 gm		☐ Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)							
	— 2% Omument 100 gm			MEDIC	CAL INFORMATION					
	PLEASE FAX COPY OF I			RD, FRON	T AND BACK, AS W		NICAL NOTES RE	GARDING THE	RAPY***	
PREVIOUS TH		& Failed (Dura	ition): N	ot Tolerat	ted: Contrai	ndication:		Q S	}	
Methotrexate)				/	12xx / 1/1	· V)	
	Cyclosporine									
Tacrolimus								1 00		
)		
Protopic	_ ()							
<u> </u>	D ₍)					Affected Area		
PHOTOTHERAPY Tried & Failed (Duration): N				ot Tolerat	ted: Contrain		□ _{Face} □ _{Fe} □ _{Nails} □ _S			as
UVA /UVB						— Naiis — S	Scoring tool u			
□ _{Patien}	nt cannot afford	Photosensitivi	ty Risk o	f Skin Can	ncer Distance fr	om Office	□ _{BSA} □ _E	ASI 🗖 ISG	A D POE	ΞM
L20.9 Atopic		Moderate) C	(Moderate to S	evere)		l	SCORAD _	% or Sc	ore:	
Other:			Dat	e of Diagr	nosis:/		Allergies:			
Active TB is rule	ed out:	o Date:	1 1		Hep B ruled out/treate	ed: \square_{Yes}	□ _{No Date:}	1 1		
	nical Information:	Dale			Tiop o Tuleu ouvileati	ou. — 165	— NO Date			
				INJE	CTION TRAINING					
	Patient has received pen	and injection	training Ph		office to provide injecti	on training C	Senderra to coo	rdinate injection	training	
	signing this form and utilizing our	services, you are	also authorizing Sende		RIBER SIGNATURE as your prior authorization d	esignated agent in deal	ling with medical and pr	escription insurance	companies, and	co-pay
assistance foundati Prescriber:	ons.						Date:			
CONFIDENTIALITY NOTICE										

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.